Lesbian /Gay Health

AIDS and HIV Related Research

The National Institutes of Health (NIH) has provided national and international leadership in the fight against AIDS. Much of this effort depends on the ability of NIH to recruit patients infected with HIV and other volunteers for inpatient and outpatient studies of new drugs and vaccines. In order to recruit subjects, it is vitally important that information be available to the community.

Following is an updated list of studies for which the NIH is currently recruiting. Of special urgency are studies involving AZT and interferon which have both been in the news recently because of remarkable new developments. Much more needs to be learned about how to use them, however, and how to use potentially less toxic alternatives such as AZDU. Please be aware that after the initial screening visit, travel costs and medical care associated with these studies are free.

HIV Infection

Alpha Interferon/IL2- Patients with HIV infection and at least 200 CD4/mm3 are sought for a phase I trial of alpha interferon in combination with interleukin-2. Contact: Dianne Lee, RN (301)496-7196.

AZT/Interferon 3 Arm Study- AZT vs. AZT + Alpha interferon vs. Alpha interferon- This 3-arm, randomized, unblinded study seeks HIV-infected persons with a CD4 count of at least 500/mm3 for a study comparing the efficacy of each of the 3 treatments. Contact: Victoria Davey, RN (301)496-7196.

AZT/IL2- Patients with HIV infection and at least 200 CD4 cells/mm3 are sought for aphase I trial of AZT in combination with interleukin-2. Contact: Dianne Lee, RN (301)496-7196.

GM-CSF/AZT/Alpha Interferon-This study is designed to evaluate the safety, toxicity and efficacy of giving granulocytemacrophage colony stimulating factor in combination with AZT and Interferon in

HIV infected persons with CD4 Counts of 200-500/mm3. Contact: Victoria Davey, RN (301)496-7196

AzdU- For the first human trials of 3'Azido-2',3'-dideoxyuridine (AzdU), patients with CD4 counts between 200 and 400/mm3 are sought. Contact: Dianne Lee, RN (301)496-7196.

AS-101 and AZT-This phase I trial designed to obtain toxicity and preliminary data of AS-101 and AZT seeks HIV-infected persons able to tolerate AZT (or have no prior exposure to it) and with CD4 counts of <200/mm3 or <20% lymphocytes. Contact: Debbie Ogata-Arakaki, RN (301)496-9565.

Bronchoscopy Study-This is a diagnostic study to evaluate the lung tissue and pulmonary status of persons who are HIV infected. Contact: Debbie Ogata-Arakaki, RN (301)496-9565.

Normal Volunteers

Vaccine (gp160)- This is a phase I trial of an AIDS vaccine, recombinant HIV-envelope protein (gp 160). We are seeking healthy men who are HIV antibody negative to participate in this study. Contact: Margaret Easter, RN (301)496-7196.


Pneumocystis Pneumonia

Piritrexim-This is a study designed to evaluate the toxicity and efficacy of oral piritrexim and leucovorin for therapy of PCP untreated for the current episode. Contact: Donna O'Neill, RN (301)496-9565.

PCP Prophylaxis- This is a phase I/II study designed to evaluate the toxicity and tolerance of weekly dapsone or dapsone/pyrimethamine in HIV-infected persons with prior history of PCP or who have less than 250/mm3 CD4 cells. Contact: Debbie Ogata-Arakaki, RN (301)496-9565.

(Continued on page 8)

For confidential AIDS Information



Call 1-800-882-AIDS

Join OITM!

Come to our Open House

Friday, Oct 6th 7:30-9:30 pm 30 Elmwood Ave, Burlington (Above VT CARES)



BARBARA Du BOIS

PhD

Psychotherapy

P.O. Box 157 Bristol, VT 05443 802/453-4960 Insurance Accepted No Charge for Phone Consultation

David M. Ross, ACSW

Certified Clinical Social Worker Individual, Couples & Group Therapy Deeply Respectful

Bollan House 96 South UnionStreet Burlington, Vt. 05401

105 Hill St., Barre, Vt. 05641

(802) 862-3101

(802) 479-2115